Participant Flow:



Baseline Characteristics:

Variable		Control group (n=3)	Intervention group (n=3)
Sex[a]	**male**	2	2
	female	1	1
Age[b]		68.9±9.2	59.6±12.9
Lesion site[a]	**brainstem**	2	1
	cerebellum	1	2
Time from stroke to inclusion (days)[b]		4±2.6	2.3±1.5
mRS[b]		3.7±0.6	3.3±0.6
SARA Heel-shin slide[b]		0.2±0.3	0.7±0.8
SARA Stance[b]		2.7±0.6	3±0
SARA Gait[b]		4.7±1.2	4±1
BBS[b]		35.7±1.5	33.4±7.2
FAC[b]		2.3±0.6	2.3±0.6

Abbreviations: mRS: modified Rankin Scale; SARA: Scale for the Assessment and Rating of Ataxia; BBS: Berg Balance Scale; FAC: Functional Ambulation Categories.
[a]Counted number of participants or lesion sites
[b]Mean ± SD

Outcome measures:

	Group	Baseline	Post Intervention	Difference	p-Value
BBS	Control (n=3)	35.7±1.5	49.3±5.8	13.7±4.7	
	Intervention (n=3)	33.3±7.2	50.7±6.8	17.3±2.1	p<0.01
FAC	Control (n=3)	2.3±0.6	4.3±0.6	2.0±1.0	
	Intervention (n=3)	2.3±0.6	4.7±0.6	2.3±0.6	

Data are mean ± SD; Abbreviations: BBS: Berg Balance Scale; FAC: Functional Ambulation Categories;

Feasibility/ Adverse Events:

	Criteria	Aim	Pilot trial	Success
Process	Eligibility rate	14%	3.5% (95% CI 1.8, 6.2%)	no
Resources	Recruitment rate	50%	63.6% (95% CI 30.8, 89.1%	yes
	Dropout rate	≤20%	14.3% (95% CI 0.4, 57.9%)	yes
Assessments and Interventions	Baseline/ post-intervention testing ≤ 60 minutes	>95%	100%	yes
	Can all assessments planned be conducted at baseline	>85% of the assessments	90% of the assessments	yes
	Can all assessments planned be conducted at post-intervention	>85% of the assessments	100% of the assessments	yes
	Treatment compliance and acceptability (attendance, duration, etc.) Intervention Group	>90%	100%	yes
	Treatment compliance and acceptability (attendance, duration, etc.) Control Group	>90%	100%	yes
	Adverse Events (in …% of the patients)	<15 %	**0 %**	yes
Organisation	Instructed therapists on study site during study period	Min. 1 out of 2 therapists	Min. 1 out of 2 therapists	yes
	10 interventions, BL and PI testing in planned time frame (16±2 days) feasible	>90%	100%	yes

Abbreviations: 95% CI: 95% confidence interval; BL: baseline; PI: post-intervention;

There were no adverse events associated with this trial.